Orion Infusions (DHA:ORIONINFU) ROCE % : 26.71% (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Orion Infusions ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Orion Infusions's annualized ROCE % for the quarter that ended in Dec. 2024 was 26.71%.

Orion Infusions ROCE % Historical Data

The historical data trend for Orion Infusions's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orion Infusions ROCE % Chart

Orion Infusions Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

ROCE %

Get a 7-Day Free Trial

28.45

27.76

29.65

24.03

25.46

Orion Infusions Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															23.81	22.52	26.30	27.68	26.71

Orion Infusions ROCE % Calculation

Orion Infusions's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	85.165	/	( ( (836.703 - 509.046)	+	(824.743 - 483.51) )	/ 2 )
	=	85.165	/	( (327.657	+	341.233)	/ 2 )
	=	85.165	/	334.445
	=	25.46 %

Orion Infusions's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	92.164	/	( ( (825.307 - 473.928)	+	(844.116 - 505.396) )	/ 2 )
	=	92.164	/	( ( 351.379	+	338.72 )	/ 2 )
	=	92.164	/	345.0495
	=	26.71 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Orion Infusions (DHA:ORIONINFU) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Orion Infusions ROCE % Related Terms

Thank you for viewing the detailed overview of Orion Infusions's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Orion Infusions Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orion Infusions Ltd (DHA:ORIONINFU) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

153-154 Tejgaon I/A, Orion House, Dhaka, BGD, 1208

Website

https://www.orioninfusion.com

Orion Infusions Ltd is a pharmaceutical company. It produces various types of intravenous fluids, rehydration solutions, electrolyte solutions, antimicrobial products, and other pharmaceutical products in Bangladesh. The products of the company include Dextrolac, Dextropac, Dextrosal, Dianak, Electro dex, fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the company is also involved in activities related to cosmetics and toiletries, infrastructure development, real estate and construction, power, agro products, hospitality, textiles and garments, and aviation management sectors. Geographically, it operates in Bangladesh.

Orion Infusions Headlines

No Headlines